Based on the core value of “integrity,” Diamond Biofund, with the approval of the Board of Directors, has established internal regulations such as the “Ethical Management Code,” “Ethical Management Operating Procedures and Behavioral Guidelines,” and the “Code of Ethical Conduct.” These regulations require the Board of Directors, management, and all employees to adhere to and implement ethical practices. To ensure the implementation of ethical management, the Company has established an effective accounting system and internal control system. Internal audit personnel regularly audit compliance with these practices and report to the Board of Directors. The Human Resources unit under the Administration Department is responsible for promoting ethical management. This includes revising the Ethical Management Operating Procedures and Behavioral Guidelines, conducting ethical management education and training, and promoting ethical management practices. The implementation of ethical management is reported annually to the Board of Directors. On April 17, 2023, a report on the implementation of ethical management for 2022 was presented to the Board, and the implementation for 2023 was reported on February 29, 2024. In 2023, there were no incidents of corruption, bribery, or other violations of ethical management.
Diamond Biofund has established the “Significant Information Processing and Insider Trading Prevention Operating Procedures,” clearly defining the applicable scope, target groups, and related procedures. This is to prevent the company’s directors, managers, and other insiders from unintentionally or intentionally violating insider trading regulations due to unfamiliarity with the law, thereby protecting investors and safeguarding the company’s interests.
Each January, the Company notifies directors of the dates for regular board meetings and reminds them not to trade company stock during the closed period, which is 15 days before the quarterly financial report announcement and 30 days before the annual financial report announcement. In addition, the Company conducted an internal training session on the prevention of insider trading for all employees on December 5, 2025. The training totaled three hours, with 22 attendances, aiming to strengthen compliance awareness and ensure adherence to relevant regulations.
Diamond Biofund has established a “Whistleblowing Policy,” set up and publicized a whistleblowing mailbox, and implemented a whistleblower protection system. The receiving unit is independent and ensures that whistleblower files are encrypted for protection. The company provides channels for internal and external personnel to report illegal acts, violations of the Code of Ethical Conduct, or breaches of the Ethical Management Code. If company employees or external personnel discover illegal activities, violations of company policies, systems, or the Code of Ethical Conduct, or actions that harm the company’s interests, such as fraud, embezzlement of company assets, leaking company secrets, or receiving improper benefits, they can report these incidents, on a named or anonymous basis, via mail or email:
The company will conduct an investigation based on the “Whistleblowing Policy” and is committed to protecting whistleblowers. The company ensures that whistleblowers will not face dismissal, demotion, salary reduction, damage to legally or contractually entitled rights, or any other adverse treatment due to their whistleblowing. Additionally, the company is responsible for keeping the whistleblower’s identity, the content of the whistleblowing, and the investigation process confidential, and will not disclose any information that could identify the whistleblower.
Diamond Biofund has internally established the “Ethical Management Code” and the “Ethical Management Operating Procedures and Behavioral Guidelines,” which are publicly disclosed on the company website. Specific regulations are outlined as follows:
| Diamond Biofund’s Political Activity Contributions | (Unit: NT$) |
| Item | 2023 |
| Lobbying Interest Donations | 0 |
| Local, Regional, or National Political Activity Donations | 0 |
| Donations to Tax-Exempt Organizations such as Trade Associations or Political Think Tanks | 0 |
| Other Contributions Related to Referendums or Ballot Activities | 0 |
醣基生醫股份有限公司
2017年9月27日登錄興櫃市場交易 (6586:TT)
公司所在地
台北,台灣
公司設立日期
2013
登錄公開市場
2017
公司官網
https://www.chopharma.com/cn/index.html